• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CPX-351（Vyxeos）可导致急性髓系白血病患者出现严重皮疹——一例病例报告。

CPX-351 (Vyxeos) can cause severe rash in acute myeloid leukemia-A case report.

作者信息

Urbantat Ruth M, Popper Valentin, Menschel Elisabeth, Pfeilstöcker Michael, Forjan Ernst, Nader Alexander, Sieghart Catherine R, Keil Felix, Koller Elisabeth

机构信息

OeGK-Hanusch Krankenhaus Vienna Austria.

Medizinische Universität Vienna Austria.

出版信息

Clin Case Rep. 2021 Feb 12;9(4):1933-1936. doi: 10.1002/ccr3.3909. eCollection 2021 Apr.

DOI:10.1002/ccr3.3909
PMID:33936618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077323/
Abstract

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

摘要

CPX-351是一种有前景的治疗与治疗相关及继发性急性髓系白血病患者的新药，可能会导致严重的全身性皮疹。尽管严重副作用罕见，但在专科中心进行治疗时仍应仔细监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3389/8077323/d31cfb986c49/CCR3-9-1933-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3389/8077323/d31cfb986c49/CCR3-9-1933-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3389/8077323/d31cfb986c49/CCR3-9-1933-g001.jpg

相似文献

1
CPX-351 (Vyxeos) can cause severe rash in acute myeloid leukemia-A case report.CPX-351（Vyxeos）可导致急性髓系白血病患者出现严重皮疹——一例病例报告。
Clin Case Rep. 2021 Feb 12;9(4):1933-1936. doi: 10.1002/ccr3.3909. eCollection 2021 Apr.
2
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.EMA 审查柔红霉素和阿糖胞苷包封在脂质体中（Vyxeos，CPX-351）用于治疗新诊断的成人、治疗相关的急性髓系白血病或伴骨髓增生异常相关改变的急性髓系白血病。
Oncologist. 2020 Sep;25(9):e1414-e1420. doi: 10.1634/theoncologist.2019-0785. Epub 2020 Apr 13.
3
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.CPX-351 对比 7+3 方案用于治疗新诊断的高危/中危继发性 AML 老年患者的无疾病症状或毒性生存质量调整时间（Q-TWiST）分析。
J Hematol Oncol. 2021 Jul 13;14(1):110. doi: 10.1186/s13045-021-01119-w.
4
CPX-351 (vyxeos) in AML.CPX-351（Vyxeos）在 AML 中的应用。
Leuk Lymphoma. 2020 Feb;61(2):288-297. doi: 10.1080/10428194.2019.1660970. Epub 2019 Sep 24.
5
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.重新定义急性髓系白血病：脂质体阿糖胞苷和柔红霉素（CPX-351）作为继发性急性髓系白血病的新兴疗法。
Onco Targets Ther. 2018 Jun 12;11:3425-3434. doi: 10.2147/OTT.S141212. eCollection 2018.
6
Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.CPX-351 在新诊断的高危/次级急性髓系白血病患者的 3 期研究中的医疗资源利用情况。
J Med Econ. 2020 Jul;23(7):714-720. doi: 10.1080/13696998.2020.1744613. Epub 2020 Apr 10.
7
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.对三种急性髓系白血病诱导化疗方案的回顾性分析，包括CPX-351、含或不含克拉屈滨的阿糖胞苷/柔红霉素。
Leuk Lymphoma. 2022 Nov;63(11):2645-2651. doi: 10.1080/10428194.2022.2092855. Epub 2022 Jul 5.
8
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.FDA 批准概要：（柔红霉素和阿糖胞苷）脂质体注射剂用于治疗高危急性髓系白血病的成人患者。
Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.
9
Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.脂质体柔红霉素-阿糖胞苷（CPX-351）在治疗新诊断的继发性急性髓细胞白血病中的应用：老药新用。
Best Pract Res Clin Haematol. 2019 Jun;32(2):127-133. doi: 10.1016/j.beha.2019.05.005. Epub 2019 May 13.
10
Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia.AML-score 在接受 CPX-351 强化诱导化疗治疗继发性急性髓系白血病的老年患者中的验证。
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):e206-e212. doi: 10.1016/j.clml.2021.09.016. Epub 2021 Sep 24.

引用本文的文献

1
The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX-351) in Acute Myeloid Leukemia Patients: A Systematic Review.阿糖胞苷与柔红霉素脂质体（CPX-351）治疗急性髓系白血病患者的临床安全性与有效性：一项系统评价
Cancer Rep (Hoboken). 2025 May;8(5):e70199. doi: 10.1002/cnr2.70199.
2
Dermatologic complications in transplantation and cellular therapy for acute leukemia.急性白血病移植和细胞治疗的皮肤并发症。
Best Pract Res Clin Haematol. 2023 Jun;36(2):101464. doi: 10.1016/j.beha.2023.101464. Epub 2023 Apr 6.
3
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.

本文引用的文献

1
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness.老年急性髓系白血病患者的治疗选择：身体状况的问题。
Cancers (Basel). 2020 Jan 2;12(1):120. doi: 10.3390/cancers12010120.
2
Sulfonamide Allergies.磺胺类药物过敏。
Pharmacy (Basel). 2019 Sep 11;7(3):132. doi: 10.3390/pharmacy7030132.
3
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.FDA 批准概要：（柔红霉素和阿糖胞苷）脂质体注射剂用于治疗高危急性髓系白血病的成人患者。
CPX-351：一种用于治疗高危急性髓系白血病的新配方旧方案。
Cancers (Basel). 2022 Jun 8;14(12):2843. doi: 10.3390/cancers14122843.
Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.
4
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.CPX-351（阿糖胞苷和柔红霉素）脂质体注射液与常规阿糖胞苷联合柔红霉素治疗新诊断的老年继发性急性髓系白血病患者的比较。
J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.
5
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
6
Cutaneous manifestations in leukemia patients.白血病患者的皮肤表现。
Semin Oncol. 2016 Jun;43(3):359-65. doi: 10.1053/j.seminoncol.2016.02.020. Epub 2016 Feb 23.
7
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
8
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.继发和治疗相关性急性髓系白血病的流行病学和临床意义：一项全国基于人群的队列研究。
J Clin Oncol. 2015 Nov 1;33(31):3641-9. doi: 10.1200/JCO.2014.60.0890. Epub 2015 Aug 24.
9
Florid skin rash in acute myeloid leukaemia.急性髓系白血病中的皮疹
BMJ Case Rep. 2013 Mar 28;2013:bcr2012008159. doi: 10.1136/bcr-2012-008159.
10
Images in clinical medicine. Palmar-plantar rash with cytarabine therapy.临床医学影像。阿糖胞苷治疗引起的掌跖皮疹。
N Engl J Med. 2011 Jan 20;364(3):e5. doi: 10.1056/NEJMicm1006530.